Objective： To observe the clinical efficacy of Taizishen Wuweizi Decoction combined with low-dose Budesonide and Formoterol Fumarate Powder Inhalant in the treatment of chronic persistent asthma in children.

Methods

2

A total of 82 children with asthma in chronic persistent stage were included and randomly divided into the treatment group （42 cases） and the control group （40 cases）. The children in the control group were treated with conventional dose Budesonide and Formoterol Fumarate Powder Inhalant， and the children in the treatment group were treated with Taizishen Wuweizi Decoction orally combined with low-dose Budesonide and Formoterol Fumarate Powder Inhalant， with a course of 3 months. The clinical efficacy of the two groups was evaluated. The acute attacks of the two groups were compared. Before and after treatment， the traditional Chinese medicine syndrome scores of the two groups were evaluated and compared. Before and after treatment， the levels of serum total immunoglobulin E （TIgE） and fractional exhaled nitric oxide （FeNO） in the two groups were detected， and the ratios of measured value to the predicted value of forced expiratory volume in one second （FEV1） and forced vital capacity （FVC） and FEV1/FVC ratio in the two groups were compared.

Results

2

In the course of treatment， two children in the treatment group were eliminated. Finally， 40 cases in the treatment group and 40 cases in the control group were included in the statistical analysis. ①After treatment， there was no statistically significant difference on clinical efficacy between the two groups （

P

>

0.05）. ②In the course of 3-month treatment， six children in the treatment group and eleven children in the control group had acute attacks of asthma， with no statistically significant difference between the two groups （

P

>

0.05）. ③After treatment， the scores of all the traditional Chinese medicine syndromes in the two groups were significantly decreased compared with those before treatment （

P

<

0.05）， and the scores of phlegm， sweating， diet and stool syndromes in the treatment group were lower than those in the control group （

P

<

0.05）. ④After treatment， the ratio of measured value to the predicted value of FEV1 in the treatment group was increased compared with that before treatment （

P

<

0.05）， and the ratios of measured value to the predicted value of FEV1 and FVC and FEV1/FVC ratio in the treatment group were higher than those in the control group （

P

<

0.05）. ⑤After treatment， the level of TIgE in the two groups was decreased compared with that before treatment （

P

<

0.05）， the level of FeNO in the treatment group was also decreased compared with that before treatment （

P

<

0.05）， and the level of TIgE in the treatment group was lower than that in the control group （

P

<

0.05）.

Conclusion

2

Taizishen Wuweizi Decoction orally combined with low-dose Budesonide and Formoterol Fumarate Powder Inhalant can effectively improve the clinical symptoms in children with asthma in chronic persistent stage， reduce the risk of acute asthma attack， and improve the pulmonary function.